These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26179624)

  • 1. Targeting the gastrointestinal tract to develop novel therapies for HIV.
    Reeves RK; Burgener A; Klatt NR
    Clin Pharmacol Ther; 2015 Oct; 98(4):381-6. PubMed ID: 26179624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression.
    Basilissi M; Tincati C; Merlini E; Ancona G; Borghi E; Borgo F; Barassi A; d'Arminio Monforte A; Marchetti G
    PLoS One; 2019; 14(2):e0212075. PubMed ID: 30763359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV and mucosal barrier interactions: consequences for transmission and pathogenesis.
    Burgener A; McGowan I; Klatt NR
    Curr Opin Immunol; 2015 Oct; 36():22-30. PubMed ID: 26151777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunity in HIV infection: what can be done to restore gastrointestinal-associated lymphoid tissue function?
    George MD; Asmuth DM
    Curr Opin Infect Dis; 2014 Jun; 27(3):275-81. PubMed ID: 24739345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities.
    Hladik F; Doncel GF
    Antiviral Res; 2010 Dec; 88 Suppl 1(Suppl 1):S3-9. PubMed ID: 21109065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HIV mucosal infection and research development of its blocking biological technique].
    Qiu SG; Zhu JQ; Zhang XY
    Bing Du Xue Bao; 2010 Nov; 26(6):500-3. PubMed ID: 21344757
    [No Abstract]   [Full Text] [Related]  

  • 7. Mucosal immune dysfunction in AIDS pathogenesis.
    Paiardini M; Frank I; Pandrea I; Apetrei C; Silvestri G
    AIDS Rev; 2008; 10(1):36-46. PubMed ID: 18385779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-Associated Interactions Between Oral Microbiota and Mucosal Immune Cells: Knowledge Gaps and Future Directions.
    Coker MO; Cairo C; Garzino-Demo A
    Front Immunol; 2021; 12():676669. PubMed ID: 34616391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV chemotherapy.
    Richman DD
    Nature; 2001 Apr; 410(6831):995-1001. PubMed ID: 11309630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th17 cells, HIV and the gut mucosal barrier.
    Dandekar S; George MD; Bäumler AJ
    Curr Opin HIV AIDS; 2010 Mar; 5(2):173-8. PubMed ID: 20543596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrovirus meeting. Gut assumes sinister new role in HIV pathogenesis.
    Cohen J
    Science; 2005 Mar; 307(5714):1395. PubMed ID: 15746401
    [No Abstract]   [Full Text] [Related]  

  • 12. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inductive/effector mechanisms for humoral immunity at mucosal sites.
    Wright PF
    Am J Reprod Immunol; 2011 Mar; 65(3):248-52. PubMed ID: 21223423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study.
    Wandeler G; Gsponer T; Bihl F; Bernasconi E; Cavassini M; Kovari H; Schmid P; Battegay M; Calmy A; Egger M; Furrer H; Rauch A;
    J Infect Dis; 2013 Nov; 208(9):1454-8. PubMed ID: 23901088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.
    Trono D; Van Lint C; Rouzioux C; Verdin E; Barré-Sinoussi F; Chun TW; Chomont N
    Science; 2010 Jul; 329(5988):174-80. PubMed ID: 20616270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus.
    Beltrán LM; Rubio-Navarro A; Amaro-Villalobos JM; Egido J; García-Puig J; Moreno JA
    Vasc Health Risk Manag; 2015; 11():35-48. PubMed ID: 25609975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protecting the initial site of viral entry: an alternative HIV vaccine target.
    Lopalco L; Bomsel M
    Expert Rev Vaccines; 2011 Sep; 10(9):1253-6. PubMed ID: 21919613
    [No Abstract]   [Full Text] [Related]  

  • 18. Complement in different stages of HIV infection and pathogenesis.
    Speth C; Stoiber H; Dierich MP
    Int Arch Allergy Immunol; 2003 Apr; 130(4):247-57. PubMed ID: 12740525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection and the gastrointestinal tract.
    Kotler DP
    AIDS; 2005 Jan; 19(2):107-17. PubMed ID: 15668535
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune responses to HIV in the female reproductive tract, immunologic parallels with the gastrointestinal tract, and research implications.
    Shacklett BL; Greenblatt RM
    Am J Reprod Immunol; 2011 Mar; 65(3):230-41. PubMed ID: 21223420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.